肝细胞癌放疗的生存结果与射频消融相当:一项倾向性评分分析
研究连续纳入≤3个早期肝细胞癌病灶且肿瘤直径≤3 cm、接受射频消融或放疗的患者,经倾向性评分匹配各106例后比较。放疗3年局部复发率显著低于射频消融(5.3% vs 12.9%,P<0.01),3年总生存率两者相当(70.4% vs 69.1%,P=0.86)。结论认为放疗局部控制优异、总生存相当,对不适合射频消融的患者似乎是可接受的替代治疗选择。
要点
- 倾向性评分匹配后放疗与射频消融3年总生存率相当(70.4% vs 69.1%,P=0.86)。
- 未匹配比较中放疗3年局部复发率显著低于射频消融(5.3% vs 12.9%,P<0.01)。
- 匹配未能平衡肿瘤与危险器官的毗邻关系及初治或挽救治疗状态。
核心结论
- 在肝功能代偿良好的患者中,放疗具有优异的局部控制且总生存与射频消融相当,显示出优势特征并弥补了其他治疗方式的不足;对不适合射频消融的患者,放疗似乎是可接受的替代治疗选择。
研究设计与样本
- 研究回顾性比较了2012年至2016年间连续接受射频消融或放疗的早期肝细胞癌患者,纳入标准为≤3个病灶且肿瘤直径≤3 cm。
- 射频消融为不适合手术的肝细胞癌的首选治疗;否则主要采用五次分次的立体定向体部放疗;对毗邻胃肠道的肝细胞癌采用轻度大分割放疗。
- 共231例患者474个肿瘤接受射频消融,143例患者221个肿瘤接受放疗;采用倾向性评分匹配以减少两组间的选择偏倚。
主要发现
- 未匹配比较中,放疗3年局部复发率为5.3%(95%CI 2.7-9.2),射频消融为12.9%(95%CI 9.9-16.2),放疗显著低于射频消融(P<0.01)。
- 倾向性评分匹配每组各106例,成功平衡了巴塞罗那临床肝癌分期、T分期和肿瘤大小,但未平衡肿瘤与危险器官的毗邻关系及初治或挽救治疗状态。
- 匹配后射频消融与放疗的3年总生存率分别为69.1%(95%CI 58.2-77.7)和70.4%(95%CI 58.5-79.4),两者相当(P=0.86)。
临床怎么用
- 作者认为,对不适合射频消融的早期肝细胞癌患者,放疗似乎是可接受的替代治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Potentially curative treatments for early-stage hepatocellular carcinoma (HCC) have drawbacks and contraindications. Recently, radiotherapy has achieved good outcomes. We compared the outcomes of radiotherapy and radiofrequency ablation (RFA) for early-stage HCC. Consecutive patients with ≤3 early-stage HCC lesions and tumor diameters ≤3 cm treated with RFA or radiotherapy were reviewed. RFA was the first choice for HCC unsuitable for surgery. Otherwise, stereotactic body radiotherapy in five fractions was mainly performed. For HCC adjacent to the gastrointestinal tract, radiotherapy with mild hypofractionation was performed. Propensity score matching was performed to reduce the selection bias between the RFA and radiotherapy groups. Between 2012 and 2016, a total of 231 patients with 474 tumors and 143 patients with 221 tumors were eligible and were treated with RFA and radiotherapy, respectively. In an unmatched comparison, the 3-year local recurrence rate was significantly lower for radiotherapy than for RFA (5.3%; 95% confidence interval [CI], 2.7-9.2; versus 12.9%, 95% CI, 9.9-16.2) (P < 0.01). A propensity score matching analysis of 106 patients in each group successfully matched the two treatment groups with regard to Barcelona Clinic Liver Cancer staging, T stage, and tumor size but not the adjacency of the tumor to risk organs or first or salvage treatment. The 3-year overall survival rates for RFA and radiotherapy patients were comparable (69.1%; 95% CI, 58.2-77.7; and 70.4%; 95% CI, 58.5-79.4, respectively; P = 0.86). Conclusion: Radiotherapy has excellent local control and comparable overall survival in patients with well-compensated liver function, exhibiting advantageous characteristics and compensating for the deficiencies of other treatment modalities; radiotherapy appears to be an acceptable alternative treatment option for patients who are not candidates for RFA.
引用
- Hara K, Takeda A, Tsurugai Y, et al. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology. 2019. PMID: 30805950. doi:10.1002/hep.30591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。